These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 31306201)

  • 41. Frequency and significance of physiological versus pathological uptake of 68Ga-DOTATATE in the pancreas: validation with morphological imaging.
    Mapelli P; Tam HH; Sharma R; Aboagye EO; Al-Nahhas A
    Nucl Med Commun; 2014 Jun; 35(6):613-9. PubMed ID: 24686250
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gallium-68-dotatate PET/CT is better than CT in the management of somatostatin expressing tumors: First experience in Africa.
    Lawal IO; Ololade KO; Lengana T; Reyneke F; Ankrah AO; Ebenhan T; Vorster M; Sathekge MM
    Hell J Nucl Med; 2017; 20(2):128-133. PubMed ID: 28697189
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular imaging of late somatostatin receptor-positive metastases of renal cell carcinoma in the pancreas by 68Ga DOTATOC PET/CT: a rare differential diagnosis to multiple primary pancreatic neuroendocrine tumors.
    Peter L; Sänger J; Hommann M; Baum RP; Kaemmerer D
    Clin Nucl Med; 2014 Aug; 39(8):713-6. PubMed ID: 24561680
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 177 Lu-DOTATATE (Lutathera) Therapy in 68 Ga-DOTATATE PET/CT-Negative Liver Metastases of a Neuroendocrine Tumor.
    Ventura D; Roll W; Kasper HU; Rahbar K; Stegger L
    Clin Nucl Med; 2023 Dec; 48(12):e585-e587. PubMed ID: 37883194
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment.
    Guenter R; Aweda T; Carmona Matos DM; Jang S; Whitt J; Cheng YQ; Liu XM; Chen H; Lapi SE; Jaskula-Sztul R
    Surgery; 2020 Jan; 167(1):189-196. PubMed ID: 31629542
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Incidental finding of a breast carcinoma on Ga-68-DOTA-1-Nal3-octreotide positron emission tomography/computed tomography performed for the evaluation of a pancreatic neuroendocrine tumor: A case report.
    Sampaio Vieira T; Borges Faria D; Souto Moura C; Francisco E; Barroso S; Pereira de Oliveira J
    Medicine (Baltimore); 2018 Sep; 97(36):e11878. PubMed ID: 30200073
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased Uptake in Microcystic Serous Cystadenoma Mimicking Pancreatic Neuroendocrine Tumor on 68 Ga-DOTATATE PET/MRI.
    Gao J; Liu C; Zhou J; Lin X; Zhang Y
    Clin Nucl Med; 2023 Nov; 48(11):987-988. PubMed ID: 37756486
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Added value of [
    Yoo J; Kim SH; Jeon SK; Bae JS; Han JK
    Eur Radiol; 2021 Oct; 31(10):7734-7745. PubMed ID: 33787974
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adrenocorticotropic Hormone-Secreting Neuroendocrine Tumor of the Rectum Demonstrated on 68Ga-DOTATATE and 18F-FDG PET Imaging.
    Szajer J; Yung G; Russo R; Mansberg R
    Clin Nucl Med; 2017 Oct; 42(10):773-775. PubMed ID: 28759524
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Quantification of immunohistochemical expression of somatostatin receptors in neuroendocrine tumors using 68Ga-DOTATATE PET/CT].
    Haug AR; Assmann G; Rist C; Tiling R; Schmidt GP; Bartenstein P; Hacker M
    Radiologe; 2010 Apr; 50(4):349-54. PubMed ID: 20333502
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metastasis From Clear Cell Renal Cell Carcinoma Mimicking Well-Differentiated Pancreatic Neuroendocrine Tumor at 18F-FDG and 68Ga-DOTATOC PET/CT.
    Guglielmo P; Pesella F; Sartorello A; El Khouzai B; Berti S; Muccioli S; Gregianin M
    Clin Nucl Med; 2022 Jul; 47(7):e498-e499. PubMed ID: 35675141
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
    J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ACR Practice Parameter for the Performance of Gallium-68 DOTATATE PET/CT for Neuroendocrine Tumors.
    Subramaniam RM; Bradshaw ML; Lewis K; Pinho D; Shah C; Walker RC
    Clin Nucl Med; 2018 Dec; 43(12):899-908. PubMed ID: 30394933
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of (68)Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1).
    Lastoria S; Marciello F; Faggiano A; Aloj L; Caracò C; Aurilio M; D'Ambrosio L; Di Gennaro F; Ramundo V; Camera L; De Luca L; Fonti R; Napolitano V; Colao A
    Endocrine; 2016 Jun; 52(3):488-94. PubMed ID: 26242621
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Incidental 68Ga-DOTATATE uptake in the pancreatic head: A case report and a unique opportunity to improve clinical care.
    Lakhotia R; Jhawar S; Malayeri AA; Millo C; Del Rivero J; Ahlman MA
    Medicine (Baltimore); 2020 May; 99(22):e20197. PubMed ID: 32481385
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recurrence of Extramedullary Plasmacytomas Involving Lymph Nodes and Pancreas Revealed by 68Ga-DOTATATE and 18F-FDG PET/CT.
    Pan Q; Luo Y; Li J; Zhang S; Li F
    Clin Nucl Med; 2018 Dec; 43(12):936-938. PubMed ID: 30179917
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Correlation of 68Ga-DOTATATE uptake on PET/CT with pathologic features of cellular proliferation in neuroendocrine neoplasms.
    Karls S; Gold R; Kravets S; Wang Y; Cheng S; Perez K; Chan J; Jacene H
    Ann Nucl Med; 2021 Sep; 35(9):1066-1077. PubMed ID: 34146243
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Observation on enhanced avidity on somatostatin receptor targeted 68Ga-DOTATATE PET-CT following therapy with everolimus and capecitabine-temozolamide: is redifferentiation akin phenomenon a reality in neuroendocrine tumors?
    Basu S; Ostwal V
    Nucl Med Commun; 2016 Jun; 37(6):669-71. PubMed ID: 27105440
    [No Abstract]   [Full Text] [Related]  

  • 59. Treatment with octreotide does not reduce tumor uptake of (68)Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors.
    Haug AR; Rominger A; Mustafa M; Auernhammer C; Göke B; Schmidt GP; Wängler B; Cumming P; Bartenstein P; Hacker M
    J Nucl Med; 2011 Nov; 52(11):1679-83. PubMed ID: 21976529
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Brain Metastases of a Neuroendocrine Tumor Visualized by 68Ga-DOTATATE PET/CT.
    Hoberück S; Michler E; Zöphel K; Platzek I; Kotzerke J; Brogsitter C
    Clin Nucl Med; 2019 Jan; 44(1):50-52. PubMed ID: 30371585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.